InvestorsHub Logo
Followers 829
Posts 119625
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Monday, 05/08/2023 4:08:52 PM

Monday, May 08, 2023 4:08:52 PM

Post# of 2959
ENTA reports phase-2 data for EDP-235:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-phase-2

It looks like the 400mg (higher) dose will be the one to be advanced to phase-3, although the PR does not explicitly say this.

EDP-235 did not show a benefit versus placebo in viral load, but this is not surprising insofar as other SARS-Cov-2 inhibitors have been unable to do that.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News